Related Experiment Video
Updated: Jun 9, 2025
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Tumor-targeted glutathione oxidation catalysis with ruthenium nanoreactors against hypoxic osteosarcoma
Hanchen Zhang1,2, Nicolás Montesdeoca3, Dongsheng Tang1,2
1Beijing National Laboratory for Molecular Sciences, Laboratory of Polymer Physics and Chemistry, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.
Abstract:
The majority of anticancer agents have a reduced or even complete loss of a therapeutic effect within hypoxic tumors. To overcome this limitation, research efforts have been devoted to the development of therapeutic agents with biological mechanisms of action that are independent of the oxygen concentration. Here we show the design, synthesis, and biological evaluation of the incorporation of a ruthenium (Ru) catalyst into polymeric nanoreactors for hypoxic anticancer therapy. The nanoreactors can catalyze the oxidation of glutathione (GSH) to glutathione disulfide (GSSG) in hypoxic cancer cells. This initiates the buildup of reactive oxygen species (ROS) and lipid peroxides, leading to the demise of cancer cells. It also stimulates the overexpression of the transient receptor potential melastatin 2 (TRPM2) ion channels, triggering macrophage activation, leading to a systemic immune response. Upon intravenous injection, the nanoreactors can systemically activate the immune system, and nearly fully eradicate an aggressive osteosarcoma tumor inside a mouse model.
Insights
This study introduces novel ruthenium-loaded nanoreactors that overcome low oxygen in tumors. These nanoreactors activate an immune response, effectively eradicating aggressive osteosarcoma in mice.
Area of Science:
- Biomedical Engineering
- Materials Science
- Oncology
Background:
- Hypoxic tumors significantly reduce the efficacy of conventional anticancer drugs.
- Developing oxygen-independent therapeutic strategies is crucial for effective cancer treatment.
Purpose of the Study:
- To design, synthesize, and evaluate polymeric nanoreactors containing a ruthenium catalyst for targeted hypoxic cancer therapy.
- To investigate the mechanism of action, including glutathione oxidation, reactive oxygen species generation, and immune system activation.
Main Methods:
- Synthesis of ruthenium-loaded polymeric nanoreactors.
- In vitro evaluation of nanoreactor-catalyzed glutathione oxidation and subsequent cellular responses.
- In vivo studies using a mouse model of aggressive osteosarcoma to assess tumor eradication and systemic immune activation.
Main Results:
- Nanoreactors effectively catalyzed glutathione oxidation in hypoxic cancer cells, leading to increased reactive oxygen species and lipid peroxides.
- This process stimulated transient receptor potential melastatin 2 (TRPM2) ion channel overexpression and macrophage activation.
- Intravenous administration of nanoreactors resulted in systemic immune activation and near-complete eradication of osteosarcoma tumors in mice.
Conclusions:
- Ruthenium-loaded nanoreactors offer a promising strategy for hypoxic cancer therapy by leveraging oxygen-independent mechanisms.
- The nanoreactors induce both direct cancer cell death and a potent systemic anti-tumor immune response.
- This approach demonstrates significant potential for treating aggressive solid tumors, such as osteosarcoma.
